Pharmacologic Study of Oseltamivir in Healthy Volunteers
Overview
"Pharmacologic Study of Oseltamivir in Healthy Volunteers" is a Phase I study in which 8 to 32 adult healthy Thai volunteers will be randomized to one of four drug doses and regimens within each of 4 visits. The study is being conducted at the Bangkok Hospital of Tropical Diseases Research Unit, Faculty of Tropical Medicine, and commenced enrolling healthy volunteers on 23 November 2006. The duration of the study is expected to be approximately four months. The goals of this study are to assess the use of loading dose oseltamivir and the concomitant use of probenecid and to characterize the pharmacokinetic properties of oseltamivir in Thai subjects.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Health Services Research
- Masking: None (Open Label)
- Study Primary Completion Date: April 2007
Interventions
- Drug: oseltamivir
- Drug: probenecid
Clinical Trial Outcome Measures
Primary Measures
- AUC 0-12 hrs.
- Time Frame: 12 hour
Secondary Measures
- AUC 12-24 hrs.
- Time Frame: 24 hrs
- C max
- Time Frame: 24 hrs
- t max
- Time Frame: 24 hrs
- t 1/2
- Time Frame: 24 hrs
Participating in This Clinical Trial
Inclusion Criteria
- healthy with no underlying chronic disease – normal baseline laboratory screening – no regular prescribed medication used in the past 30 days and no over-the-counter medication in the past week – agree to abstain from self-medication during the study – negative urine pregnancy test for females and agreement that they will not try to become pregnant until 1 month after the study is completed – only use non-hormonal methods of contraception for females – non-smoker for the last 30 days and for duration of the study – no consumption of alcohol for the last 30 days and for duration of the study – no use of recreational drugs for the last 30 days and for duration of the study Exclusion Criteria:
- known hypersensitivity to oseltamivir and/or probenecid – Hepatitis B virus surface antigen positive – presence of intercurrent illness or any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 45 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Mahidol University
- Collaborator
- National Institute of Allergy and Infectious Diseases (NIAID)
- Provider of Information About this Clinical Study
- Yupaporn Wattanagoon, Faculty of Tropical Medicine, Mahidol University
- Overall Official(s)
- Yupaporn Wattanagoon, DTM & H, Principal Investigator, Associate Professor, Department of Clinical Tropical Medicine Faculty of Tropical Medicine, Mahidol University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.